Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Receivables - Other (2021 - 2024)

Historic Receivables - Other for Universe Pharmaceuticals (UPC) over the last 5 years, with Q3 2025 value amounting to $3.3 billion.

  • Universe Pharmaceuticals' Receivables - Other fell 4177.12% to $3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year decrease of 4177.12%. This contributed to the annual value of $3.3 billion for FY2025, which is 4177.12% down from last year.
  • According to the latest figures from Q3 2025, Universe Pharmaceuticals' Receivables - Other is $3.3 billion, which was down 4177.12% from $5.7 billion recorded in Q3 2024.
  • Universe Pharmaceuticals' 5-year Receivables - Other high stood at $5.7 billion for Q3 2024, and its period low was $236982.0 during Q3 2021.
  • Over the past 5 years, Universe Pharmaceuticals' median Receivables - Other value was $391.6 million (recorded in 2023), while the average stood at $1.9 billion.
  • Its Receivables - Other has fluctuated over the past 5 years, first surged by 134715.5% in 2024, then plummeted by 4177.12% in 2025.
  • Over the past 5 years, Universe Pharmaceuticals' Receivables - Other (Quarter) stood at $236982.0 in 2021, then soared by 50.34% to $356290.0 in 2022, then skyrocketed by 109801.48% to $391.6 million in 2023, then surged by 1347.16% to $5.7 billion in 2024, then tumbled by 41.77% to $3.3 billion in 2025.
  • Its last three reported values are $3.3 billion in Q3 2025, $5.7 billion for Q3 2024, and $391.6 million during Q3 2023.